Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)
Shots: Endevica Bio conducting P-II study in collaboration with WuXi Clinical repo...
Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
Shots: The P-III (ACHIEVE-1) trial assessed orforglipron vs PBO in T2D adults (n=5...
BriaCell Reveals P-II Trial Data of Bria-IMT Regimen for Metastatic Breast Cancer
Shots: BriaCell has reported P-II trial data comparing Bria-IMT + check point inhi...
Telix Pharmaceuticals Reports Preliminary P-II (IPAX-Linz) Trial Data of TLX101 to Treat Glioma
Shots: The IIT P-II (IPAX-Linz) trial assessed TLX101 (IV) in 8 glioblastoma...
Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management
Shots: Pfizer has discontinued the development of danuglipron (PF-06882961) as a p...
Amgen Reports P-III (DeLLphi-304) Trial Findings of Imdelltra for SCLC
Shots: Amgen has reported P-III (
